Please login to the form below
asthma drug
This page shows the latest asthma drug news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca and Avillion’s asthma rescue treatment granted FDA approval
Airsupra significantly reduces the risk of severe asthma exacerbations. AstraZeneca (AZ) and Avillion’s Airsupra, formerly known as PT027, has been approved by the US Food and Drug Administration (FDA) as ... There are an estimated 136 million asthma
Latest news
-
Sanofi and Regeneron share positive data for asthma drug
The trial evaluated the drug for children aged six to 11 years with moderate-to-severe asthma. ... age group with moderate-to-severe asthma and evidence of type 2 inflammation.
-
Tezepelumab effective in severe asthma with comorbid nasal polyps
Amgen’s novel drug offers hope to the one-in-five people with severe asthma who also have nasal polyps. ... Amgen has announced new data showing its first-in-class asthma drug tezepelumab reduced exacerbations and improved lung function in patients
-
FDA grants priority review for AZ, Amgen’s tezepelumab for asthma
Drug 'has the potential to transform treatment for a broad population of severe asthma patients'. ... The US Food and Drug Administration (FDA) has accepted AstraZeneca (AZ) and Amgen’s submission for their investigational asthma drug tezepelumab and
-
AZ, Amgen file first-in-class asthma drug with the FDA
AstraZeneca (AZ) and Amgen have submitted a biologic license application (BLA) for their first-in-class asthma drug tezepelumab to the US Food and Drug Administration (FDA). ... In September 2018, tezepelumab scored a breakthrough therapy designation (BTD
-
FDA approves new self-injection administration for Xolair
Drug is approved for asthma and other allergic and inflammatory conditions. ... This includes a number of allergic and inflammatory conditions, including moderate-to-severe persistent allergic asthma, chronic idiopathic urticaria (CIU) and nasal polyps.
More from news
Approximately 2 fully matching, plus 129 partially matching documents found.
Latest Intelligence
-
GSK forges ahead with its dynamic COPD and asthma portfolio
You would imagine coronavirus would be one of those threats.”. GSK is trialling its biologic anti IL-5 drug mepolizumab, licensed for severe asthma, in eosinophilic COPD with a new phase ... The company is also forging ahead with biologics research in
-
The long and winding road to asthma breakthroughs
This was the turning point for the development programme.”. The late nights interrogating the science and unpicking data sets prompted the switch from a drug for the broad asthma community to ... a therapy targeted at a subtype representing around 10%
-
Cancer immunotherapy: What's on the horizon?
Researchers are now trying to identify biomarker-based subgroups and drug combinations to try to improve therapeutic outcomes for patients. ... up innate immune responses, and Cancer Research UK is repurposing an AZ chemokine CCR4 receptor drug (AZD2098)
-
US health reforms
In fact, it’s safe to say most C-suite drug executives would hardly shed a tear upon news of Obamacare’s swift demise. ... To cite just one example, patients with financial need get an 85% discount on the popular asthma drug Advair, and that’s by
-
Building BRICs: pharma's key emerging markets are becoming giants
In April 2013, Novartis was denied patent protection for its cancer drug, Glivec, by the Indian Supreme Court. ... This follows similar patent defeats in India for Pegasys, Roche's hepatitis drug, Merck's asthma treatment, Singulair, Gilead's Viread (HIV)
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest appointments
-
Enterprise Therapeutics appoints CEO
He joins the drug discovery firm from Xention Discovery, where he had served as chief scientific officer since co-founding the company in 2002. ... Discovery. Dr Peter Finan, chairman of Enterprise Therapeutics, said: “John's experience in ion channels,
-
Former RBS head takes the reins as GSK chair
the past year, and to develop new products in order to offset the decline of its best-selling asthma drug, Advair, as part of his new remit.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study
- ICR and Merck renew strategic alliance for development of new cancer drugs
- DeepMind’s AI tool classifies effects of mutations in genetic diseases
- CDC awards over $23m to Johns Hopkins Center for Health Security project
- Looking to start activity on a currently unpromoted pharmaceutical brand?
- Considering a portfolio review?
No results were found
PMHub
Healthcare Media Europe – HME Ltd
HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
